Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer.

De Braganca KC, Janjigian YY, Azzoli CG, Kris MG, Pietanza MC, Nolan CP, Omuro AM, Holodny AI, Lassman AB.

J Neurooncol. 2010 Dec;100(3):443-7. doi: 10.1007/s11060-010-0200-2. Epub 2010 May 4.

2.

Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study.

Besse B, Le Moulec S, Mazières J, Senellart H, Barlesi F, Chouaid C, Dansin E, Bérard H, Falchero L, Gervais R, Robinet G, Ruppert AM, Schott R, Léna H, Clément-Duchêne C, Quantin X, Souquet PJ, Trédaniel J, Moro-Sibilot D, Pérol M, Madroszyk AC, Soria JC.

Clin Cancer Res. 2015 Apr 15;21(8):1896-903. doi: 10.1158/1078-0432.CCR-14-2082. Epub 2015 Jan 22.

3.

Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases.

Socinski MA, Langer CJ, Huang JE, Kolb MM, Compton P, Wang L, Akerley W.

J Clin Oncol. 2009 Nov 1;27(31):5255-61. doi: 10.1200/JCO.2009.22.0616. Epub 2009 Sep 8.

PMID:
19738122
4.

A phase II study of oxaliplatin, pemetrexed, and bevacizumab in previously treated advanced non-small cell lung cancer.

Heist RS, Fidias P, Huberman M, Ardman B, Sequist LV, Temel JS, Lynch TJ.

J Thorac Oncol. 2008 Oct;3(10):1153-8. doi: 10.1097/JTO.0b013e318187273f.

5.

BRIDGE: an open-label phase II trial evaluating the safety of bevacizumab + carboplatin/paclitaxel as first-line treatment for patients with advanced, previously untreated, squamous non-small cell lung cancer.

Hainsworth JD, Fang L, Huang JE, Karlin D, Russell K, Faoro L, Azzoli C.

J Thorac Oncol. 2011 Jan;6(1):109-14. doi: 10.1097/JTO.0b013e3181f94ad4.

6.

FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme.

Cohen MH, Shen YL, Keegan P, Pazdur R.

Oncologist. 2009 Nov;14(11):1131-8. doi: 10.1634/theoncologist.2009-0121. Epub 2009 Nov 6.

7.

Molecularly targeted therapy using bevacizumab for non-small cell lung cancer: a pilot study for the new CT response criteria.

Lee HY, Lee KS, Hwang HS, Lee JW, Ahn MJ, Park K, Kim TS, Yi CA, Chung MJ.

Korean J Radiol. 2010 Nov-Dec;11(6):618-26. doi: 10.3348/kjr.2010.11.6.618. Epub 2010 Oct 29.

8.

Bevacizumab-Based Therapy for Patients with Brain Metastases from Non-Small-Cell Lung Cancer: Preliminary Results.

Zustovich F, Ferro A, Lombardi G, Farina P, Zagonel V.

Chemotherapy. 2014;60(5-6):294-9. doi: 10.1159/000376605. Epub 2015 May 20.

PMID:
25999127
9.

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.

Gadgeel SM, Gandhi L, Riely GJ, Chiappori AA, West HL, Azada MC, Morcos PN, Lee RM, Garcia L, Yu L, Boisserie F, Di Laurenzio L, Golding S, Sato J, Yokoyama S, Tanaka T, Ou SH.

Lancet Oncol. 2014 Sep;15(10):1119-28. doi: 10.1016/S1470-2045(14)70362-6. Epub 2014 Aug 18.

PMID:
25153538
10.

A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC).

Raez LE, Santos ES, Webb RT, Wade J, Brito RA, Karr M, Kennah A, Childs BH.

Cancer Chemother Pharmacol. 2013 Nov;72(5):1103-10. doi: 10.1007/s00280-013-2301-z. Epub 2013 Sep 22.

PMID:
24057043
11.

Salvage therapy with single agent bevacizumab for recurrent glioblastoma.

Chamberlain MC, Johnston SK.

J Neurooncol. 2010 Jan;96(2):259-69. doi: 10.1007/s11060-009-9957-6. Epub 2009 Jul 11.

PMID:
19593660
12.

Targeting angiogenesis for treatment of NSCLC brain metastases.

Schettino C, Bareschino MA, Rossi A, Maione P, Sacco PC, Colantuoni G, Rossi E, Gridelli C.

Curr Cancer Drug Targets. 2012 Mar;12(3):289-99. Review.

PMID:
22229249
13.

Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study.

Crinò L, Dansin E, Garrido P, Griesinger F, Laskin J, Pavlakis N, Stroiakovski D, Thatcher N, Tsai CM, Wu YL, Zhou C.

Lancet Oncol. 2010 Aug;11(8):733-40. doi: 10.1016/S1470-2045(10)70151-0. Epub 2010 Jul 23.

PMID:
20650686
14.

Salvage gamma knife stereotactic radiosurgery followed by bevacizumab for recurrent glioblastoma multiforme: a case-control study.

Park KJ, Kano H, Iyer A, Liu X, Niranjan A, Flickinger JC, Lieberman FS, Lunsford LD, Kondziolka D.

J Neurooncol. 2012 Apr;107(2):323-33. doi: 10.1007/s11060-011-0744-9. Epub 2011 Nov 5.

PMID:
22057917
15.

Safety and efficacy of first-line bevacizumab with chemotherapy in Asian patients with advanced nonsquamous NSCLC: results from the phase IV MO19390 (SAiL) study.

Tsai CM, Au JS, Chang GC, Cheng AC, Zhou C, Wu YL.

J Thorac Oncol. 2011 Jun;6(6):1092-7. doi: 10.1097/JTO.0b013e318216687d.

16.

Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas.

Gutin PH, Iwamoto FM, Beal K, Mohile NA, Karimi S, Hou BL, Lymberis S, Yamada Y, Chang J, Abrey LE.

Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):156-63. doi: 10.1016/j.ijrobp.2008.10.043. Epub 2009 Jan 23.

17.
18.

Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.

Herbst RS, O'Neill VJ, Fehrenbacher L, Belani CP, Bonomi PD, Hart L, Melnyk O, Ramies D, Lin M, Sandler A.

J Clin Oncol. 2007 Oct 20;25(30):4743-50. Epub 2007 Oct 1.

PMID:
17909199
19.

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.

Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, Kesari S, Wen PY.

Neurology. 2008 Mar 4;70(10):779-87. doi: 10.1212/01.wnl.0000304121.57857.38.

PMID:
18316689
20.

Phase II study of docetaxel-plus-bevacizumab combination therapy in patients previously treated for advanced non-squamous non-small cell lung cancer.

Ohyanagi F, Yanagitani N, Kudo K, Kawano Y, Sakatani T, Tanimoto A, Nishizawa H, Horiike A, Hagiwara S, Horai T, Nishio M.

Anticancer Res. 2014 Sep;34(9):5153-8.

PMID:
25202107

Supplemental Content

Support Center